Epidemiology and Infectious DiseasesEpidemiology and Infectious Diseases1560-95292411-3026Eco-Vector4176510.17816/EID41765Review ArticlePreventive vaccination of pneumococcal disease under the dissemination of COVID-19NikiforovVladimir V.<p>MD, PhD, Prof., Head of the Department of Infectious Diseases and Epidemiology</p>v.v.nikiforov@gmail.comhttps://orcid.org/0000-0002-2205-9674OrlovaNatalia V.<p>MD, PhD, Prof.</p>vrach315@yandex.ruhttps://orcid.org/0000-0002-4293-3285SuranovaTatyana G.<p>MD, PhD, Assistant Prof.</p>suranovatatiana@mail.ruhttps://orcid.org/0000-0003-3411-1027MironovAndrey Yu.<p>MD, PhD, Prof.</p>andy.60@mail.ruhttps://orcid.org/0000-0002-8544-5230PolezhaevaNatalya A.<p>MD.</p>natashapolezh@yandex.ruPirogov Russian National Research Medical UniversityFederal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological AgencyFederal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency»All-Russian center for disaster medicine “Zashchita”G.N.Gabrichevsky Research Institute for Epidemiology and Microbiology1504202025248552707202005092020Copyright © 2020, Eco-vector2020<p>Under the coronavirus disease 2019 (COVID-19) pandemic, special attention should be paid to minimize the morbidity risk of all infections controlled by specific prophylaxis. During preparation for the epidemic season, the organization and conduct of vaccination against influenza and pneumococcal infection is a particularly crucial task of public health. Priority immunization should be provided to patients from epidemiological and social risk groups. This article presents an overview of the data on pneumococcal infection vaccination efficiency in various population groups as well as on its reasonability for preventing superimposed infection development in COVID-19 infection. In addition to children and decreed groups of the adult population, vaccination against pneumococcal infection is indicated for patients with chronic diseases. This enables us to reduce the risk of complications in case of a new coronavirus infection. Particular attention should be paid to immunizing medical personnel, who are at high risk of infection, play a significant role in controlling the pandemic, and need protection. With the continuous spread of COVID-19, vaccination is necessary in compliance with additional measures to ensure safety (patient routing, disinfection intensification in vaccination rooms, etc.).</p>pneumococcal infectionStreptococcus pneumoniaerisk groupspreventive vaccinationпневмококковая инфекцияStreptococcus pneumoniaeгруппы рискавакцинопрофилактика[Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on preventive vaccination against pneumococcal infections in adults. Russian Pulmonology. 2019;29(1):19-34. (In Russ). doi: 10.18093/0869-0189-2019-29-1-19-34.][Beloshitskiy GV, Korolyova IS, Mironov KO. Phenotypic and genotypic characteristics of pneumococci isolated from patients with pneumococcal meningitis. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2011;13(3):261-266. (In Russ).][Briko NI. Epidemiologiya, klinika i profilaktika pnevmokokkovoi infektsii: Uchebnoe posobie dlya vrachei. Nizhnii Novgorod: Remedium Privolzh’e; 2017. (In Russ).][Tatochenko VK, Ozeretskovskii NA. Immunoprofilaktika-2018: Spravochnik. 13th ed. Moscоw: Borges; 2018. (In Russ).][McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018;67(10):1498-1506. doi: 10.1093/cid/ciy312.][Instruction for Prevenar13 LP-000798-041016 [Internet]. (In Russ). Available from: https://medi.ru/instrukciya/prevenar-13_15117/.][Nurkka A, Ahman H, Korkeila M, et al. Serum and salivary anti-antibodies in infantsand children immunized with heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20(1):25-33. doi: 10.1097/00006454-200101000-00006.][Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-318. doi: 10.1093/cid/cit816.][Center for Disease Control and Prevention. Pneumococcal Diseases. Pneumococcal Vaccination. Available at: https://www.cdc.gov/pneumococcal/vaccination.html.][Tsaim CJ, Griffin MR, Nuorti JP, Grijalva CG. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis. 2008;46(11):1664-1172. doi: 10.1086/587897.][Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365(9465):1139-1146. doi: 10.1016/S0140-6736(05)71876-6.][Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010;340:1004. doi: 10.1136/bmj.c1004.][Reinert R, Taysi B. Effectiveness of the 13-valent pneumococcal conjugate vaccine: emerging data from invasive pneumococcal disease, pneumonia, acute otitis media and nasopharyngeal carriage. Pediatric pharmacology. 2012;9(3):8-11. (In Russ). doi: 10.15690/pf.v9i3.315.][Jacobs DM, Yung F, Hart E, et al. Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States. Vaccine. 2017;35(45):6160-6165. doi: 10.1016/j.vaccine.2017.09.050.][Webber C, Patton M, Patterson S, et al. Exploratory efficacy endpoints in the Community − Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Vaccine. 2017;35(9):1266-1272. doi: 10.1016/j.vaccine.2017.01.032.][Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127-9131. doi: 10.1016/j.vaccine.2011.09.112.][Moore M, Link-Gelles R, Farley M, et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), US, 2010–2011: International symposium on pneumococci and pneumococcal diseases, ISPPD-8; 2011 Mar 11–15. Poster 179. Iguacu Falls, Brazil; 2012.][Chuchalin AG, Onischenko GG, Kolosov VP, et al. Clinical and epidemiological assessment of the effectiveness of vaccination of children against pneumococcal infection in the Amur region. Journal of Microbiology, Epidemiology and Immunobiology. 2016;(3):57-63. (In Russ). doi: 10.36233/0372-9311-2016-3-57-63.][Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1(1):CD001390. doi: 10.1002/14651858.CD001390.pub4.][Ignatova GL, Antonov VN. Epidemiological characteristics of chronic respiratory diseases in patients vaccinated against pneumococcal infection. Pulmonologiia. 2017;27(3):376-383. (In Russ). doi: 10.18093/0869-0189-2017-27-3-376-383.][Briko NI, Korshunov VA, Vasilyeva IA, Vorobieva AD. Vaccination against pneumococcal infection in adults from risk groups. Tuberculosis and Lung Diseases. 2020;98(5):15-23. (In Russ). doi: 10.21292/2075-1230-2020-98-5-15-23.]